Novo Nordisk A/S (NYSE: NVO) experienced a significant stock decline on Friday following the release of disappointing clinical trial results for its experimental drug ziltivekimab. The Danish pharmaceutical giant saw its Copenhagen-listed shares drop approximately 7% to around DKK308, while U.S.-traded American Depositary Receipts (ADRs) fell 9.0% to $46.96, erasing roughly $20.5 billion in market capitalization.
The negative market reaction was driven by data from the Phase 3 ZEUS trial, which evaluated ziltivekimab in over 6,300 patients with cardiovascular disease, chronic kidney disease, and systemic inflammation. The trial's primary endpoint, a composite of major adverse cardiovascular events (MACE) including cardiovascular death, heart attack, and stroke, yielded a hazard ratio of 0.99 compared to placebo. This result was far worse than the 0.85 threshold that analysts had considered the minimum acceptable level for regulatory and commercial viability.
ZEUS Trial Results and Market Impact
The hazard ratio of 0.99 indicates essentially no reduction in cardiovascular events, with a 95% confidence interval of 0.88 to 1.11, which includes 1.00 and thus fails to demonstrate statistical significance. The trial also reported a higher rate of serious infections in the ziltivekimab group, although overall serious adverse events were similar between groups. Novo's Chief Scientific Officer, Martin Holst Lange, acknowledged that the biological impact observed in the trial "did not result in MACE benefits."
The market's reaction was severe, with Novo underperforming Eli Lilly and Company (NYSE: LLY) by 7.5 percentage points and the Health Care Select Sector SPDR Fund (NYSEARCA: XLV) by approximately 8.0 points. The selloff reflects a broader reassessment of Novo's pipeline valuation, as the loss in market value was roughly 28 times the $725 million acquisition cost of Corvidia Therapeutics, which Novo purchased in 2020 to obtain ziltivekimab.
Reliance on Obesity and Diabetes Portfolio
This setback is particularly troubling for Novo Nordisk, which remains heavily dependent on its GLP-1 franchise. In the first quarter of 2026, obesity and diabetes therapies accounted for 94.0% of adjusted sales, with obesity treatments generating DKK20.912 billion (29.8% of total) and diabetes treatments DKK44.936 billion (64.1%). The rare disease segment contributed only DKK4.215 billion (6.0%).
The company's reliance on this narrow product range amplifies the impact of pipeline failures. Ziltivekimab was seen as a potential diversification opportunity, offering a monthly anti-inflammatory treatment for cardiovascular disease, a large and growing market. The failure of ZEUS removes this potential multibillion-dollar asset from Novo's development prospects, according to analysts at JPMorgan Chase & Co. (NYSE: JPM).
Financial Outlook and Upcoming Results
Despite the setback, Novo Nordisk affirmed that the ZEUS results will not affect its adjusted profit forecast for 2026. The company plans to take a non-cash impairment charge in the third quarter. Its existing guidance calls for adjusted operating profit to decline by 4% to 12% in constant currencies.
Investors now look ahead to the company's first-half results, scheduled for release on August 5. Key focus areas will include Wegovy shipment figures, U.S. net pricing trends, and the full-year outlook. The ZEUS disappointment places greater emphasis on the performance of Novo's core business to support its valuation.
While the complete ZEUS data may reveal beneficial patient subgroups, the higher infection rate poses challenges for future development. Additional trials, HERMES and ARTEMIS, are still ongoing, with results expected in the first half of 2027. However, the market's immediate reaction underscores the high stakes and risks inherent in pharmaceutical development, particularly for a company so concentrated in a few therapeutic areas.
